Brandywine Global Investment Management LLC Takes $51.11 Million Position in Humana Inc. (NYSE:HUM)

Brandywine Global Investment Management LLC bought a new position in shares of Humana Inc. (NYSE:HUM) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 201,432 shares of the insurance provider’s stock, valued at approximately $51,105,000.

Several other large investors have also recently bought and sold shares of the stock. Allianz SE bought a new stake in Humana in the 4th quarter valued at $3,549,000. Allstate Corp bought a new stake in shares of Humana in the fourth quarter valued at about $905,000. Orion Portfolio Solutions LLC grew its stake in shares of Humana by 3.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider’s stock valued at $1,226,000 after acquiring an additional 171 shares in the last quarter. denkapparat Operations GmbH bought a new position in Humana during the fourth quarter worth about $323,000. Finally, Pictet Asset Management Holding SA raised its stake in Humana by 18.8% in the 4th quarter. Pictet Asset Management Holding SA now owns 72,803 shares of the insurance provider’s stock worth $18,471,000 after purchasing an additional 11,523 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.37% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $263.95 on Friday. The company has a market capitalization of $31.86 billion, a PE ratio of 26.53, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a fifty day simple moving average of $270.14 and a 200 day simple moving average of $273.87.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. Humana’s dividend payout ratio is currently 35.58%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HUM. Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Barclays increased their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Eighteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.